Market Overview

UPDATE: Cantor Fitzgerald Initiates Coverage on Bruker

Share:
Related BRKR
BTIG Downgrades Bruker, Still Likes Long-Term Story
Benzinga's Top Downgrades
Healthcare ratings roundup (Seeking Alpha)

According to a research report published Thursday, Cantor Fitzgerald has initiated Bruker (NASDAQ: BRKR) with a Buy rating and $16 PT.

In the report, Cantor Fitzgerald said, "Bruker has a highly diversified high-end scientific instrumentation portfolio targeting life science, applied, and industrial markets. In our view, the company is well positioned to capitalize on high-growth market segments over the next several years and deliver above-market top line growth, leveraging internal R&D and strategic tuckins. Additionally, with below sector average margins, Bruker has significant upside for margin expansion in the medium-term."

Bruker closed Wednesday at $13.39.

Latest Ratings for BRKR

DateFirmActionFromTo
May 2016BTIG ResearchDowngradesBuyNeutral
May 2016Leerink SwannMaintainsMarket Perform
Apr 2016Leerink SwannDowngradesOutperformMarket Perform

View More Analyst Ratings for BRKR
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Initiation Analyst Ratings

 

Related Articles (BRKR)

View Comments and Join the Discussion!